Sumitomo Mitsui Trust Group Inc. Has $8.98 Million Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Sumitomo Mitsui Trust Group Inc. lowered its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 4.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 755,970 shares of the company's stock after selling 33,252 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.99% of Nurix Therapeutics worth $8,981,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC lifted its position in shares of Nurix Therapeutics by 38.9% during the first quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock worth $109,000 after purchasing an additional 2,562 shares during the last quarter. Rhumbline Advisers lifted its holdings in Nurix Therapeutics by 7.0% during the 1st quarter. Rhumbline Advisers now owns 110,488 shares of the company's stock worth $1,313,000 after buying an additional 7,255 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Nurix Therapeutics by 202.2% during the 1st quarter. GAMMA Investing LLC now owns 14,018 shares of the company's stock worth $167,000 after buying an additional 9,380 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Nurix Therapeutics by 3.0% during the 4th quarter. Wellington Management Group LLP now owns 3,586,605 shares of the company's stock worth $67,572,000 after buying an additional 104,500 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in Nurix Therapeutics during the 4th quarter worth approximately $28,000.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,198 shares of the stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34. Following the transaction, the chief financial officer directly owned 33,724 shares of the company's stock, valued at $382,092.92. This represents a 15.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the transaction, the insider directly owned 61,516 shares in the company, valued at $707,434. The trade was a 5.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,013 shares of company stock worth $137,096. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Stock Performance

NASDAQ:NRIX traded down $0.37 during trading hours on Monday, hitting $12.36. 740,524 shares of the company's stock traded hands, compared to its average volume of 836,453. The firm has a market cap of $942.33 million, a P/E ratio of -4.41 and a beta of 2.15. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56. The stock's fifty day moving average price is $11.14 and its two-hundred day moving average price is $13.96.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 369.40% and a negative return on equity of 47.49%. The business had revenue of $18.45 million for the quarter, compared to the consensus estimate of $12.78 million. During the same period in the prior year, the business posted ($0.76) earnings per share. On average, equities research analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Analyst Upgrades and Downgrades

NRIX has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating and set a $36.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, April 2nd. Wall Street Zen raised shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. Stifel Nicolaus cut their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Leerink Partnrs raised shares of Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a report on Tuesday, April 29th. Four analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $30.18.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.